mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions

References

• Kandaswamy R, Skeans MA, Gustafson SK, et al. OPTN/SRTR 2013 annual data report: pancreas. Am J Transplant. 2015;15(Suppl 2):1–20.
   PubMed Web of Science ®Google Scholar
• Kandaswamy R, Stock PG, Skeans MA, et al. OPTN/SRTR 2011 annual data report: pancreas. Am J Transplant. 2013;13(Suppl 1):47–72.
   PubMed Web of Science ®Google Scholar
• Kimelman M, Brandacher G. Trends in immunosuppression after pancreas transplantation: what is in the pipeline? Curr Opin Organ Transplant. 2013;18:76–82.
   PubMed Web of Science ®Google Scholar
• Knight RJ, Podder H, Kerman RH, et al. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation. Transplantation. 2010;89:727–732.
   PubMed Web of Science ®Google Scholar
• Grinyo JM, Ekberg H, Mamelok RD, et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrol Dial Transplant. 2009;24:2269–2276.
   PubMed Web of Science ®Google Scholar
• Rangel EB. The metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation. Expert Opin Drug Metab Toxicol. 2012;8:1531–1548.
   PubMed Web of Science ®Google Scholar
• Drachenberg CB, Torrealba JR, Nankivell BJ, et al. Guidelines for the diagnossssis of antibody-mediated rejection in pancreas allografts-updated Banff grading schema. Am J Transplant. 2011;11:1792–1802.
   PubMed Web of Science ®Google Scholar
• Girman P, Lipar K, Koznarova R, et al. Similar early complication rate in simultaneous pancreas and kidney recipients on tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus immunosuppressive regimens. Transplant Proc. 2010;42:1999–2002.
   PubMed Web of Science ®Google Scholar
• Sageshima J, Ciancio G, Chen L, et al. Everolimus with low-dose tacrolimus in simultaneous pancreas and kidney transplantation. Clin Transplant. 2014;28:797–801.
   PubMed Web of Science ®Google Scholar
• Ciancio G, Sageshima J, Chen L, et al. Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years. Am J Transplant. 2012;12:3363–3376.
   PubMed Web of Science ®Google Scholar
• Gruessner RW, Gruessner AC. Pancreas transplant alone: a procedure coming of age. Diabetes Care. 2013;36:2440–2447.
   PubMed Web of Science ®Google Scholar
• Porubsky M, Gruessner AC, Rana A, et al. Excellent outcomes can be achieved in young pancreas transplant alone recipients by addition of sirolimus to maintenance immunosuppression regimen. Transplant Proc. 2014;46:1932–1935.
   PubMed Web of Science ®Google Scholar
• Halleck F, Duerr M, Waiser J, et al. An evaluation of sirolimus in renal transplantation. Expert Opin Drug Metab Toxicol. 2012;8:1337–1356.
   PubMed Web of Science ®Google Scholar
• Holdaas H, Midtvedt K, Asberg A. A drug safety evaluation of everolimus in kidney transplantation. Expert Opin Drug Saf. 2012;11:1013–1022.
   PubMed Web of Science ®Google Scholar
• Choi J, Chen J, Schreiber SL, et al. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science. 1996;273:239–242.
   PubMed Web of Science ®Google Scholar
• Alayev A, Holz MK. mTOR signaling for biological control and cancer. J Cell Physiol. 2013;228:1658–1664.
   PubMed Web of Science ®Google Scholar
• Lieberthal W, Levine JS. Mammalian target of rapamycin and the kidney. I. The signaling pathway. Am J Physiol Renal Physiol. 2012;303:F1–10.
   PubMed Web of Science ®Google Scholar
• Dowling RJ, Topisirovic I, Alain T, et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science. 2010;328:1172–1176.
   PubMed Web of Science ®Google Scholar
• Moes DJ, Guchelaar HJ, de Fijter JW. Sirolimus and everolimus in kidney transplantation. Drug Discov Today. 2015;20:1243–1249.
   PubMed Web of Science ®Google Scholar
• Shihab F, Christians U, Smith L, et al. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. Transpl Immunol. 2014;31:22–32.
   PubMed Web of Science ®Google Scholar
• Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet. 2001;40:573–585.
   PubMed Web of Science ®Google Scholar
• Kahan BD, Napoli KL, Podbielski J, et al. Therapeutic drug monitoring of sirolimus for optimal renal transplant outcomes. Transplant Proc. 2001;33:1278.
   PubMed Web of Science ®Google Scholar
• Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43:83–95.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Hsu CH, McMahon L, et al. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther. 2001;70:247–254.
   PubMed Web of Science ®Google Scholar
• Neumayer HH, Paradis K, Korn A, et al. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br J Clin Pharmacol. 1999;48:694–703.
   PubMed Web of Science ®Google Scholar
• Pieri M, Miraglia N, Polichetti G, et al. Analytical and pharmacological aspects of therapeutic drug monitoring of mTOR inhibitors. Curr Drug Metab. 2011;12:253–267.
   PubMed Web of Science ®Google Scholar
• Verhave J, Boucher A, Dandavino R, et al. The incidence, management, and evolution of rapamycin-related side effects in kidney transplant recipients. Clin Transplant. 2014;28:616–622.
   PubMed Web of Science ®Google Scholar
• Taber DJ, Belk L, Meadows H, et al. Racial comparisons of everolimus pharmacokinetics and pharmacodynamics in adult kidney transplant recipients. Ther Drug Monit. 2013;35:753–759.
   PubMed Web of Science ®Google Scholar
• Nashan B, Gaston R, Emery V, et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation. 2012;93:1075–1085.
   PubMed Web of Science ®Google Scholar
• Vigano M, Dengler T, Mattei MF, et al. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study. Transpl Infect Dis. 2010;12:23–30.
   PubMed Web of Science ®Google Scholar
• Ghassemieh B, Ahya VN, Baz MA, et al. Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation. J Heart Lung Transplant. 2013;32:701–706.
   PubMed Web of Science ®Google Scholar
• Sheng L, Jun S, Jianfeng L, et al. The effect of sirolimus-based immunosuppression vs. conventional prophylaxis therapy on cytomegalovirus infection after liver transplantation. Clin Transplant. 2015;29:555–559.
   PubMed Web of Science ®Google Scholar
• Kobashigawa J, Ross H, Bara C, et al. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation. Transpl Infect Dis. 2013;15:150–162.
   PubMed Web of Science ®Google Scholar
• Clippinger AJ, Maguire TG, Alwine JC. The changing role of mTOR kinase in the maintenance of protein synthesis during human cytomegalovirus infection. J Virol. 2011;85:3930–3939.
   PubMed Web of Science ®Google Scholar
• Egli A, Kumar D, Broscheit C, et al. Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling. Transplantation. 2013;95:448–455.
   PubMed Web of Science ®Google Scholar
• Havenith SH, Yong SL, van Donselaar-van der Pant KA, et al. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients. Transplantation. 2013;95:184–191.
   PubMed Web of Science ®Google Scholar
• Poglitsch M, Weichhart T, Hecking M, et al. CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages. Am J Transplant. 2012;12:1458–1468.
   PubMed Web of Science ®Google Scholar
• McMahon GM, Datta D, Bruneau S, et al. Constitutive activation of the mTOR signaling pathway within the normal glomerulus. Biochem Biophys Res Commun. 2012;425:244–249.
   PubMed Web of Science ®Google Scholar
• Godel M, Hartleben B, Herbach N, et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest. 2011;121:2197–2209.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang J, Qin L, et al. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol. 2007;27:495–502.
   PubMed Web of Science ®Google Scholar
• Inoki K, Mori H, Wang J, et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest. 2011;121:2181–2196.
   PubMed Web of Science ®Google Scholar
• Canaud G, Bienaime F, Viau A, et al. AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat Med. 2013;19:1288–1296.
   PubMed Web of Science ®Google Scholar
• Watanabe R, Wei L, Huang J. mTOR signaling, function, novel inhibitors, and therapeutic targets. J Nucl Med. 2011;52:497–500.
   PubMed Web of Science ®Google Scholar
• Sereno J, Nunes S, Rodrigues-Santos P, et al. Conversion to sirolimus ameliorates cyclosporine-induced nephropathy in the rat: focus on serum, urine, gene, and protein renal expression biomarkers. Biomed Res Int. 2014;2014:576929.
   PubMed Web of Science ®Google Scholar
• Stratakis S, Stylianou K, Petrakis I, et al. Rapamycin ameliorates proteinuria and restores nephrin and podocin expression in experimental membranous nephropathy. Clin Dev Immunol. 2013;2013:941893.
   PubMedGoogle Scholar
• Muller-Krebs S, Weber L, Tsobaneli J, et al. Cellular effects of everolimus and sirolimus on podocytes. PLoS One. 2013;8:e80340.
   PubMed Web of Science ®Google Scholar
• George B, Vollenbroker B, Saleem MA, et al. GSK3beta inactivation in podocytes results in decreased phosphorylation of p70S6K accompanied by cytoskeletal rearrangements and inhibited motility. Am J Physiol Renal Physiol. 2011;300:F1152–F1162.
   PubMed Web of Science ®Google Scholar
• Mariappan MM, Prasad S, D’Silva K, et al. Activation of glycogen synthase kinase 3beta ameliorates diabetes-induced kidney injury. J Biol Chem. 2014;289:35363–35375.
   PubMed Web of Science ®Google Scholar
• Lee JY, Chang JW, Yang WS, et al. Albumin-induced epithelial-mesenchymal transition and ER stress are regulated through a common ROS-c-Src kinase-mTOR pathway: effect of imatinib mesylate. Am J Physiol Renal Physiol. 2011;300:F1214–F1222.
   PubMed Web of Science ®Google Scholar
• Peruchetti DB, Cheng J, Caruso-Neves C, et al. Mis-regulation of mammalian target of rapamycin (mTOR) complexes induced by albuminuria in proximal tubules. J Biol Chem. 2014;289:16790–16801.
   PubMed Web of Science ®Google Scholar
• Ko HT, Yin JL, Wyburn K, et al. Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction. Nephrol Dial Transplant. 2013;28:327–336.
   PubMed Web of Science ®Google Scholar
• Hartleben B, Godel M, Meyer-Schwesinger C, et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest. 2010;120:1084–1096.
   PubMed Web of Science ®Google Scholar
• Cina DP, Onay T, Paltoo A, et al. Inhibition of MTOR disrupts autophagic flux in podocytes. J Am Soc Nephrol. 2012;23:412–420.
   PubMed Web of Science ®Google Scholar
• Yamahara K, Kume S, Koya D, et al. Obesity-mediated autophagy insufficiency exacerbates proteinuria-induced tubulointerstitial lesions. J Am Soc Nephrol. 2013;24:1769–1781.
   PubMed Web of Science ®Google Scholar
• Liu WJ, Luo MN, Tan J, et al. Autophagy activation reduces renal tubular injury induced by urinary proteins. Autophagy. 2014;10:243–256.
   PubMed Web of Science ®Google Scholar
• Li L, Wang ZV, Hill JA, et al. New autophagy reporter mice reveal dynamics of proximal tubular autophagy. J Am Soc Nephrol. 2014;25:305–315.
   PubMed Web of Science ®Google Scholar
• Velagapudi C, Bhandari BS, Abboud-Werner S, et al. The tuberin/mTOR pathway promotes apoptosis of tubular epithelial cells in diabetes. J Am Soc Nephrol. 2011;22:262–273.
   PubMed Web of Science ®Google Scholar
• Kurdian M, Herrero-Fresneda I, Lloberas N, et al. Delayed mTOR inhibition with low dose of everolimus reduces TGFbeta expression, attenuates proteinuria and renal damage in the renal mass reduction model. PLoS One. 2012;7:e32516.
   PubMed Web of Science ®Google Scholar
• Nakagawa S, Masuda S, Nishihara K, et al. mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats. Biochem Pharmacol. 2010;79:67–76.
   PubMed Web of Science ®Google Scholar
• Ramadan R, Faour D, Awad H, et al. Early treatment with everolimus exerts nephroprotective effect in rats with adriamycin-induced nephrotic syndrome. Nephrol Dial Transplant. 2012;27:2231–2241.
   PubMed Web of Science ®Google Scholar
• Nakagawa S, Nishihara K, Inui K, et al. Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury. Eur J Pharmacol. 2012;696:143–154.
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche HU, Chu AH, David KM, et al. Switching immunosuppression medications after renal transplantation–a common practice. Nephrol Dial Transplant. 2006;21:2256–2262.
   PubMed Web of Science ®Google Scholar
• Morath C, Arns W, Schwenger V, et al. Sirolimus in renal transplantation. Nephrol Dial Transplant. 2007;22(Suppl 8):viii61–viii65.
   PubMedGoogle Scholar
• Wali RK, Mohanlal V, Ramos E, et al. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant. 2007;7:1572–1583.
   PubMed Web of Science ®Google Scholar
• Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant. 2009;9:1115–1123.
   PubMed Web of Science ®Google Scholar
• Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet. 2011;377:837–847.
   PubMed Web of Science ®Google Scholar
• Diekmann F, Andres A, Oppenheimer F. mTOR inhibitor-associated proteinuria in kidney transplant recipients. Transplant Rev (Orlando). 2012;26:27–29.
   PubMedGoogle Scholar
• Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc. 2003;35:52S–57S.
   PubMed Web of Science ®Google Scholar
• Diekmann F, Budde K, Oppenheimer F, et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant. 2004;4:1869–1875.
   PubMed Web of Science ®Google Scholar
• Weir MR, Mulgaonkar S, Chan L, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int. 2011;79:897–907.
   PubMed Web of Science ®Google Scholar
• Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009;87:233–242.
   PubMed Web of Science ®Google Scholar
• Chhabra D, Alvarado A, Dalal P, et al. Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen. Am J Transplant. 2013;13:2902–2911.
   PubMed Web of Science ®Google Scholar
• Silva HT Jr., Felipe CR, Garcia VD, et al. Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients. Am J Transplant. 2013;13:3155–3163.
   PubMed Web of Science ®Google Scholar
• Murakami N, Riella LV, Funakoshi T. Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis. Am J Transplant. 2014;14:2317–2327.
   PubMed Web of Science ®Google Scholar
• Liefeldt L, Brakemeier S, Glander P, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant. 2012;12:1192–1198.
   PubMed Web of Science ®Google Scholar
• Croze LE, Tetaz R, Roustit M, et al. Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor-specific antibodies. Transpl Int. 2014;27:775–783.
   PubMed Web of Science ®Google Scholar
• Wiseman AC, McCague K, Kim Y, et al. The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes. Am J Transplant. 2013;13:442–449.
   PubMed Web of Science ®Google Scholar
• Lorber MI, Mulgaonkar S, Butt KM, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation. 2005;80:244–252.
   PubMed Web of Science ®Google Scholar
• Vitko S, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2005;5:2521–2530.
   PubMed Web of Science ®Google Scholar
• Nashan B, Curtis J, Ponticelli C, et al. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation. 2004;78:1332–1340.
   PubMed Web of Science ®Google Scholar
• Tedesco SH Jr., Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant. 2010;10:1401–1413.
   PubMed Web of Science ®Google Scholar
• Langer RM, Hene R, Vitko S, et al. Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation. Transpl Int. 2012;25:592–602.
   PubMed Web of Science ®Google Scholar
• Budde K, Lehner F, Sommerer C, et al. Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study. Am J Transplant. 2012;12:1528–1540.
   PubMed Web of Science ®Google Scholar
• Budde K, Lehner F, Sommerer C, et al. Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. Am J Transplant. 2015;15:119–128.
   PubMed Web of Science ®Google Scholar
• Budde K, Rath T, Sommerer C, et al. Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. Clin Nephrol. 2015;83:11–21.
   PubMed Web of Science ®Google Scholar
• Klawitter J, Nashan B, Christians U. Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf. 2015;14:1055–1070.
   PubMed Web of Science ®Google Scholar
• Wieland E, Olbricht CJ, Susal C, et al. Biomarkers as a tool for management of immunosuppression in transplant patients. Ther Drug Monit. 2010;32:560–572.
   PubMed Web of Science ®Google Scholar
• Vuiblet V, Birembaut P, Francois A, et al. Sirolimus-based regimen is associated with decreased expression of glomerular vascular endothelial growth factor. Nephrol Dial Transplant. 2012;27:411–416.
   PubMed Web of Science ®Google Scholar
• Letavernier E, Pe’raldi MN, Pariente A, et al. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation. 2005;80:1198–1203.
   PubMed Web of Science ®Google Scholar
• Stallone G, Infante B, Pontrelli P, et al. Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins. Transplantation. 2011;91:997–1004.
   PubMed Web of Science ®Google Scholar
• Munivenkatappa R, Haririan A, Papadimitriou JC, et al. Tubular epithelial cell and podocyte apoptosis with de novo sirolimus based immunosuppression in renal allograft recipients with DGF. Histol Histopathol. 2010;25:189–196.
   PubMed Web of Science ®Google Scholar
• Mandelbrot DA, Alberu J, Barama A, et al. Effect of ramipril on urinary protein excretion in maintenance renal transplant patients converted to sirolimus. Am J Transplant. 2015;15:3174–3184.
   PubMed Web of Science ®Google Scholar
• Kandula P, Fridell J, Taber TE, et al. Impact of tacrolimus-sirolimus maintenance immunosuppression on proteinuria and kidney function in pancreas transplant alone recipients. Transplantation. 2012;94:940–946.
   PubMed Web of Science ®Google Scholar
• Genzini T, Marchini GS, Chang AJ, et al. Influence of pancreas transplantation alone on native renal function. Transplant Proc. 2006;38:1939–1940.
   PubMed Web of Science ®Google Scholar
• Campistol JM, Cockwell P, Diekmann F, et al. Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation. Transpl Int. 2009;22:681–687.
   PubMed Web of Science ®Google Scholar
• Albano L, Berthoux F, Moal MC, et al. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation. 2009;88:69–76.
   PubMed Web of Science ®Google Scholar
• Salvadori M, Scolari MP, Bertoni E, et al. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial. Transplantation. 2009;88:1194–1202.
   PubMed Web of Science ®Google Scholar
• Robson M, Cote I, Abbs I, et al. Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant. 2003;3:324–327.
   PubMed Web of Science ®Google Scholar
• Saikali JA, Truong LD, Suki WN. Sirolimus may promote thrombotic microangiopathy. Am J Transplant. 2003;3:229–230.
   PubMed Web of Science ®Google Scholar
• Banhara PB, Goncalves RT, Rocha PT, et al. Tubular dysfunction in renal transplant patients using sirolimus or tacrolimus. Clin Nephrol. 2015;83:331–337.
   PubMed Web of Science ®Google Scholar
• Morrisett JD, Abdel-Fattah G, Hoogeveen R, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res. 2002;43:1170–1180.
   PubMed Web of Science ®Google Scholar
• Teutonico A, Schena PF, Di PS. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol. 2005;16:3128–3135.
   PubMed Web of Science ®Google Scholar
• Niclauss N, Bosco D, Morel P, et al. Rapamycin impairs proliferation of transplanted islet beta cells. Transplantation. 2011;91:714–722.
   PubMed Web of Science ®Google Scholar
• Rachdi L, Balcazar N, Osorio-Duque F, et al. Disruption of Tsc2 in pancreatic beta cells induces beta cell mass expansion and improved glucose tolerance in a TORC1-dependent manner. Proc Natl Acad Sci U S A. 2008;105:9250–9255.
   PubMed Web of Science ®Google Scholar
• Koyanagi M, Asahara S, Matsuda T, et al. Ablation of TSC2 enhances insulin secretion by increasing the number of mitochondria through activation of mTORC1. PLoS One. 2011;6:e23238.
   PubMed Web of Science ®Google Scholar
• Gu Y, Lindner J, Kumar A, et al. Rictor/mTORC2 is essential for maintaining a balance between beta-cell proliferation and cell size. Diabetes. 2011;60:827–837.
   PubMed Web of Science ®Google Scholar
• Barlow AD, Xie J, Moore CE, et al. Rapamycin toxicity in MIN6 cells and rat and human islets is mediated by the inhibition of mTOR complex 2 (mTORC2). Diabetologia. 2012;55:1355–1365.
   PubMed Web of Science ®Google Scholar
• Zammit NW, Tan BM, Walters SN, et al. Low-dose rapamycin unmasks the protective potential of targeting intragraft NF-kappaB for islet transplants. Cell Transplant. 2013;22:2355–2366.
   PubMed Web of Science ®Google Scholar
• Scheuner D, Vander MD, Song B, et al. Control of mRNA translation preserves endoplasmic reticulum function in beta cells and maintains glucose homeostasis. Nat Med. 2005;11:757–764.
   PubMed Web of Science ®Google Scholar
• Bachar-Wikstrom E, Wikstrom JD, Ariav Y, et al. Stimulation of autophagy improves endoplasmic reticulum stress-induced diabetes. Diabetes. 2013;62:1227–1237.
   PubMed Web of Science ®Google Scholar
• Bartolome A, Guillen C, Benito M. Autophagy plays a protective role in endoplasmic reticulum stress-mediated pancreatic beta cell death. Autophagy. 2012;8:1757–1768.
   PubMed Web of Science ®Google Scholar
• Schindler CE, Partap U, Patchen BK, et al. Chronic rapamycin treatment causes diabetes in male mice. Am J Physiol Regul Integr Comp Physiol. 2014;307:R434–R443.
   PubMed Web of Science ®Google Scholar
• Tanemura M, Ohmura Y, Deguchi T, et al. Rapamycin causes upregulation of autophagy and impairs islets function both in vitro and in vivo. Am J Transplant. 2012;12:102–114.
   PubMed Web of Science ®Google Scholar
• Yin H, Park SY, Wang XJ, et al. Enhancing pancreatic Beta-cell regeneration in vivo with pioglitazone and alogliptin. PLoS One. 2013;8(6):e65777.
   Web of Science ®Google Scholar
• Festuccia WT, Blanchard PG, Belchior T, et al. PPARgamma activation attenuates glucose intolerance induced by mTOR inhibition with rapamycin in rats. Am J Physiol Endocrinol Metab. 2014;306:E1046–E1054.
   PubMed Web of Science ®Google Scholar
• Shimizu S, Hosooka T, Matsuda T, et al. DPP4 inhibitor vildagliptin preserves beta-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice. J Mol Endocrinol. 2012;49:125–135.
   PubMed Web of Science ®Google Scholar
• Miao XY, Gu ZY, Liu P, et al. The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway. Peptides. 2013;39:71–79.
   PubMed Web of Science ®Google Scholar
• Shivaswamy V, Bennett RG, Clure CC, et al. Metformin improves immunosuppressant induced hyperglycemia and exocrine apoptosis in rats. Transplantation. 2013;95:280–284.
   PubMed Web of Science ®Google Scholar
• Johnston O, Rose CL, Webster AC, et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol. 2008;19:1411–1418.
   PubMed Web of Science ®Google Scholar
• Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant. 2004;4:626–635.
   PubMed Web of Science ®Google Scholar
• Rangel EB. Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions. Expert Opin Drug Metab Toxicol. 2014;10:1585–1605.
   PubMed Web of Science ®Google Scholar
• Hecking M, Haidinger M, Doller D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol. 2012;23:739–749.
   PubMed Web of Science ®Google Scholar
• Minute M, Patti G, Tornese G, et al. Sirolimus therapy in congenital hyperinsulinism: a successful experience beyond infancy. Pediatrics. 2015;136:e1373–e1376.
   PubMed Web of Science ®Google Scholar
• Fishbane S, Cohen DJ, Coyne DW, et al. Posttransplant anemia: the role of sirolimus. Kidney Int. 2009;76:376–382.
   PubMed Web of Science ®Google Scholar
• Thaunat O, Beaumont C, Chatenoud L, et al. Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation. 2005;80:1212–1219.
   PubMed Web of Science ®Google Scholar
• Thaunat O, Beaumont C, Lechaton S, et al. Late introduction of sirolimus induces anemia in renal transplant recipients. Transplantation. 2007;83:1283.
   PubMed Web of Science ®Google Scholar
• Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation. 2000;69:2085–2090.
   PubMed Web of Science ®Google Scholar
• Webster AC, Lee VW, Chapman JR, et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation. 2006;81:1234–1248.
   PubMed Web of Science ®Google Scholar
• Pallet N, Legendre C. Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf. 2013;12:177–186.
   PubMed Web of Science ®Google Scholar
• Kasiske BL, de MA, Flechner SM, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant. 2008;8:1384–1392.
   PubMed Web of Science ®Google Scholar
• Hoogeveen RC, Ballantyne CM, Pownall HJ, et al. Effect of sirolimus on the metabolism of apo. Transplantation. 2001;72:1244–1250.
   PubMed Web of Science ®Google Scholar
• Ma KL, Ruan XZ, Powis SH, et al. Sirolimus modifies cholesterol homeostasis in hepatic cells: a potential molecular mechanism for sirolimus-associated dyslipidemia. Transplantation. 2007;84:1029–1036.
   PubMed Web of Science ®Google Scholar
• Massy ZA, De Bandt JP, Morelon E, et al. Hyperlipidaemia and post-heparin lipase activities in renal transplant recipients treated with sirolimus or cyclosporin A. Nephrol Dial Transplant. 2000;15:928.
   PubMed Web of Science ®Google Scholar
• Maluf DG, Mas VR, Archer KJ, et al. Apolipoprotein E genotypes as predictors of high-risk groups for developing hyperlipidemia in kidney transplant recipients undergoing sirolimus treatment. Transplantation. 2005;80:1705–1711.
   PubMed Web of Science ®Google Scholar
• Houde VP, Brule S, Festuccia WT, et al. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes. 2010;59:1338–1348.
   PubMed Web of Science ®Google Scholar
• Riella LV, Gabardi S, Chandraker A. Dyslipidemia and its therapeutic challenges in renal transplantation. Am J Transplant. 2012;12:1975–1982.
   PubMed Web of Science ®Google Scholar
• Nashan B, Citterio F. Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature. Transplantation. 2012;94:547–561.
   PubMed Web of Science ®Google Scholar
• Langer RM, Kahan BD. Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation. 2002;74:804–808.
   PubMed Web of Science ®Google Scholar
• Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation. 2004;77:1555–1561.
   PubMed Web of Science ®Google Scholar
• Benavides C, Mahmoud KH, Knight R, et al. Rabbit antithymocyte globulin: a postoperative risk factor for sirolimus-treated renal transplant patients? Transplant Proc. 2005;37:822–826.
   PubMed Web of Science ®Google Scholar
• Rogers CC, Hanaway M, Alloway RR, et al. Corticosteroid avoidance ameliorates lymphocele formation and wound healing complications associated with sirolimus therapy. Transplant Proc. 2005;37:795–797.
   PubMed Web of Science ®Google Scholar
• Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation. 2004;77:252–258.
   PubMed Web of Science ®Google Scholar
• Dantal J, Berthoux F, Moal MC, et al. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int. 2010;23:1084–1093.
   PubMed Web of Science ®Google Scholar
• Azzola A, Havryk A, Chhajed P, et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation. 2004;77:275–280.
   PubMed Web of Science ®Google Scholar
• Mahe E, Morelon E, Lechaton S, et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation. 2005;79:476–482.
   PubMed Web of Science ®Google Scholar
• van GT, ter Meulen CG, Hene R, et al. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation. 2003;75:788–791.
   PubMed Web of Science ®Google Scholar
• Toso C, Meeberg GA, Bigam DL, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation. 2007;83:1162–1168.
   PubMed Web of Science ®Google Scholar
• Campistol JM, de Fijter JW, Flechner SM, et al. mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant. 2010;24:149–156.
   PubMed Web of Science ®Google Scholar
• Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US study group. Lancet. 2000;356:194–202.
   PubMed Web of Science ®Google Scholar
• Dereure O. Skin reactions related to treatment with anticytokines, membrane receptor inhibitors and monoclonal antibodies. Expert Opin Drug Saf. 2003;2:467–473.
   PubMedGoogle Scholar
• Mahe E, Morelon E, Lechaton S, et al. Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects. J Am Acad Dermatol. 2006;55:139–142.
   PubMed Web of Science ®Google Scholar
• Watson CJ, Firth J, Williams PF, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant. 2005;5:2496–2503.
   PubMed Web of Science ®Google Scholar
• Hardinger KL, Cornelius LA, Trulock EP III, et al. Sirolimus-induced leukocytoclastic vasculitis. Transplantation. 2002;74:739–743.
   PubMed Web of Science ®Google Scholar
• Nagarajan S, Friedrich T, Garcia M, et al. Gastrointestinal leukocytoclastic vasculitis: an adverse effect of sirolimus. Pediatr Transplant. 2005;9:97–100.
   PubMed Web of Science ®Google Scholar
• Morelon E, Stern M, Kreis H. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med. 2000;343:225–226.
   PubMed Web of Science ®Google Scholar
• Weiner SM, Sellin L, Vonend O, et al. Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome–a single-centre experience and review of the literature. Nephrol Dial Transplant. 2007;22:3631–3637.
   PubMed Web of Science ®Google Scholar
• Morelon E, Stern M, Israel-Biet D, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation. 2001;72:787–790.
   PubMed Web of Science ®Google Scholar
• Duran I, Siu LL, Oza AM, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer. 2006;42:1875–1880.
   PubMed Web of Science ®Google Scholar
• Cho D, Signoretti S, Regan M, et al. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res. 2007;13:758s–763s.
   PubMed Web of Science ®Google Scholar
• Rehm B, Keller F, Mayer J, et al. Resolution of sirolimus-induced pneumonitis after conversion to everolimus. Transplant Proc. 2006;38:711–713.
   PubMed Web of Science ®Google Scholar
• Maroto JP, Hudes G, Dutcher JP, et al. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol. 2011;29:1750–1756.
   PubMed Web of Science ®Google Scholar
• Champion L, Stern M, Israel-Biet D, et al. Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med. 2006;144:505–509.
   PubMed Web of Science ®Google Scholar
• Huyghe E, Zairi A, Nohra J, et al. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview. Transpl Int. 2007;20:305–311.
   PubMed Web of Science ®Google Scholar
• Zuber J, Anglicheau D, Elie C, et al. Sirolimus may reduce fertility in male renal transplant recipients. Am J Transplant. 2008;8:1471–1479.
   PubMed Web of Science ®Google Scholar
• Timokhina I, Kissel H, Stella G, et al. Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation. Embo J. 1998;17:6250–6262.
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Nashan B, del Carmen RM, et al. A prospective, multinational pharmacoepidemiological study of clinical conversion to sirolimus immunosuppression after renal transplantation. J Transplant. 2012;2012:107180.
   PubMedGoogle Scholar
• Yang J, Zhao X, Patel A, et al. Rapamycin inhibition of mTOR reduces levels of the Na+/H+ exchanger 3 in intestines of mice and humans, leading to diarrhea. Gastroenterology. 2015;149:151–162.
   PubMed Web of Science ®Google Scholar
• Kuypers DR. Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring. Ann Transplant. 2008;13:11–18.
   PubMed Web of Science ®Google Scholar
• Wu FL, Tsai MK, Chen RR, et al. Effects of calcineurin inhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients. Pharmacotherapy. 2005;25:646–653.
   PubMed Web of Science ®Google Scholar
• Piao SG, Bae SK, Lim SW, et al. Drug interaction between cyclosporine and mTOR inhibitors in experimental model of chronic cyclosporine nephrotoxicity and pancreatic islet dysfunction. Transplantation. 2012;93:383–389.
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Merlini S, Zenoni S, et al. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant. 2005;5:2937–2944.
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Merlini S, Pellegrino M, et al. Therapeutic drug monitoring of sirolimus: effect of concomitant immunosuppressive therapy and optimization of drug dosing. Am J Transplant. 2004;4:1345–1351.
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002;62:1060–1067.
   PubMed Web of Science ®Google Scholar
• Hubner GI, Eismann R, Sziegoleit W. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit. 1999;21:536–539.
   PubMed Web of Science ®Google Scholar
• Naito T, Shinno K, Maeda T, et al. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation. Biol Pharm Bull. 2006;29:275–280.
   PubMed Web of Science ®Google Scholar
• Kuypers DR, Claes K, Evenepoel P, et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol. 2003;43:866–880.
   PubMed Web of Science ®Google Scholar
• Pascual J, del CD, Cabello M, et al. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. Transplantation. 2010;89:994–1000.
   PubMed Web of Science ®Google Scholar
• Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med. 2016;374:333–343.
   PubMed Web of Science ®Google Scholar
• Nankivell BJ, P’Ng CH, O’Connell PJ, et al. Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras. Transplantation. 2016;100(8):1723–1731.
   PubMed Web of Science ®Google Scholar
• Prud’homme GJ, Glinka Y, Hasilo C, et al. GABA protects human islet cells against the deleterious effects of immunosuppressive drugs and exerts immunoinhibitory effects alone. Transplantation. 2013;96:616–623.
   PubMed Web of Science ®Google Scholar
• Chowdhury P, Hernandez-Fuentes MP. Non-invasive biomarkers to guide management following renal transplantation: the need for a multiplatform approach. Curr Opin Organ Transplant. 2013;18:1–5.
   PubMed Web of Science ®Google Scholar
• Merani S, Famulski KS, Ramassar V, et al. Characterization of the transcriptome in isolated and transplanted mouse pancreatic islets: associations with engraftment and dysfunction. Islets. 2012;4:158–166.
   PubMed Web of Science ®Google Scholar
• Grinyo JM, Cruzado JM. Mycophenolate mofetil and sirolimus combination in renal transplantation. Am J Transplant. 2006;6:1991–1999.
   PubMed Web of Science ®Google Scholar
• Holdaas H, Fellstrom B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant. 2005;5:2929–2936.
   PubMed Web of Science ®Google Scholar
• Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–2192.
   PubMed Web of Science ®Google Scholar
• Zsom L, Wagner L, Fulop T. Minimization vs tailoring: where do we stand with personalized immunosuppression during renal transplantation in 2015? World J Transplant. 2015;5:73–80.
   PubMedGoogle Scholar